Schizophrenia
|
0.380 |
Biomarker
|
disease |
BEFREE |
Meta-analysis established that the pooled prevalence of GAD65 autoantibodies was 5.8% (95% confidence interval [CI]: 2.0-15.6%; I<sup>2</sup> = 91%; nine studies) in psychotic disorders, with a prevalence of 4.6% (95%CI: 1.2-15.9%; nine studies; I<sup>2</sup> = 89%) and 6.2% (95%CI: 1.2-27.0%; two studies; I<sup>2</sup> = 69%) in schizophrenia and bipolar disorder, respectively.
|
28573688 |
2017 |
Schizophrenia
|
0.380 |
AlteredExpression
|
disease |
BEFREE |
Several of the genes in this network including epigenetic factors histone deacetylase 1 (HDAC1) and death-associated protein 6 (DAXX), the GABAergic enzyme GAD65 as well as the kainate receptor (KAR) subunits GluR6 and 7 show significant changes in expression in this area in SZ.
|
27733539 |
2017 |
Schizophrenia
|
0.380 |
AlteredExpression
|
disease |
BEFREE |
Moreover, the patients with schizophrenia with completed suicide or positive nicotine exposure showed significantly higher expression of GAD2 full length transcript.
|
26848839 |
2016 |
Schizophrenia
|
0.380 |
AlteredExpression
|
disease |
BEFREE |
In concert with previous studies, these findings suggest that schizoaffective disorder is associated with lower levels of both GAD65 and GAD67 mRNA and protein in the PFC, whereas subjects with schizophrenia have lower mean levels of only GAD67 mRNA and protein.
|
24993056 |
2015 |
Schizophrenia
|
0.380 |
Biomarker
|
disease |
BEFREE |
We used dual-label in situ hybridization to quantify GABA(A) α1 subunit mRNA expression in calcium/calmodulin-dependent kinase II α (CaMKIIα)-containing pyramidal cells and glutamic acid decarboxylase 65 kDa (GAD65)-containing interneurons in layer 3 of the PFC from matched schizophrenia and healthy comparison subjects.
|
21677653 |
2011 |
Schizophrenia
|
0.380 |
Biomarker
|
disease |
BEFREE |
These results suggest that GAD2 and GLUL do not play a major role in schizophrenia pathogenesis and there is no gene-gene interaction between the eight genes in the Japanese population.
|
19125103 |
2009 |
Schizophrenia
|
0.380 |
Biomarker
|
disease |
CTD_human |
Schizophrenia subjects showed significant decreases in mRNA levels of GAD(67), GAD(65), GAT-1, mGluR2, and neuronal nitric oxide synthase.
|
18923069 |
2008 |
Schizophrenia
|
0.380 |
GeneticVariation
|
disease |
BEFREE |
Using the multifactor-dimensionality reduction method (MDR), we found that the interactions among the rs187269C/T polymorphism in the GABRB2 gene, the -243A/G polymorphism in the GAD2 gene and the 27379C/T and 661C/T polymorphisms in the GAD1 gene revealed a significant association with schizophrenia (P<0.001).
|
17412563 |
2007 |
Schizophrenia
|
0.380 |
GeneticVariation
|
disease |
LHGDN |
Using the multifactor-dimensionality reduction method (MDR), we found that the interactions among the rs187269C/T polymorphism in the GABRB2 gene, the -243A/G polymorphism in the GAD2 gene and the 27379C/T and 661C/T polymorphisms in the GAD1 gene revealed a significant association with schizophrenia (P<0.001).
|
17412563 |
2007 |
Schizophrenia
|
0.380 |
Biomarker
|
disease |
CTD_human |
This study demonstrates for the first time significant deficits in GABAergic markers Reelin and GAD 65 and 67 proteins in bipolar subjects and global deficits in the latter proteins in schizophrenia and mood disorders, accounting for the reported alterations in CSF/plasma levels of glutamate and GABA in these disorders.
|
15560956 |
2005 |
Schizophrenia
|
0.380 |
AlteredExpression
|
disease |
BEFREE |
Although the levels of GAD65 and GAD67 messages were increased in schizophrenia subjects, the proportion of the two GAD isoforms remained constant in controls and schizophrenics.
|
15114630 |
2004 |
Schizophrenia
|
0.380 |
AlteredExpression
|
disease |
LHGDN |
Although the levels of GAD65 and GAD67 messages were increased in schizophrenia subjects, the proportion of the two GAD isoforms remained constant in controls and schizophrenics.
|
15114630 |
2004 |